VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Unmet needs of patients with leiomyosarcoma

Brian Van Tine • 4 Jun 2022
ASCO 2022
Sarcoma

Brian Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, talks on the need for a treatment with a low toxicity profile and significant durability for patients with leiomyosarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Brian Van Tine

0:41
Unesbulin plus dacarbazine demonstrates promising efficacy in patients with advanced leiomyosarcoma
Brian Van Tine • 3 Jun 2022
2:39
APROMISS: catequentinib in synovial sarcoma
Brian Van Tine • 8 Jun 2021
0:55
Key data in sarcoma presented at ASCO 2022
Brian Van Tine • 4 Jun 2022
1:17
Hot topics in sarcoma at ASCO 2021
Brian Van Tine • 8 Jun 2021

Related Videos

1:36
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Robin Jones
1:04
How has the trabectedin extended access program benefited sarcoma patients?
Robin Jones
2:06
The current state of drug development against sarcomas
Robin Jones
5:17
Response rates to immunotherapy in sarcoma patients and implications for future therapies
Gary Schwartz • 3 Jun 2016
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals